INS and type 2 diabetes mellitus: Recent studies have revealed that CEMA, as an acrolein exposure biomarker, could decrease insulin sensitivity and raise fasting insulin FPI, FPG, HOMA-insulin resistance, risks of prevalent IR, impaired fasting glucose, impaired fasting glucose (IFG), and the risk of type 2 diabetes, respectively (27).